Microbiome medicine accelerated by new partnership between BiomeBank and Hudson Institute

• BiomeBank and Hudson Institute sign a 4-year collaboration agreement to discover and develop microbial therapies. • BiomeBank gains exclusive license to paediatric IBD study, which identified key bacteria believed to be involved in disease onset and resolution. These bacteria were identified using a world-first method that unlocks culturing and metagenomics of colon biopsy samples. The…

0 Comments

BiomeBank appoints ex-Ellerston Capital CIO and Blackrock North Asia Director as Chair to accelerate commercialisation strategy

BiomeBank appoints Mr Chris Hall as Chair, effective 17 January 2022. Mr Hall brings over 30 years’ experience and impressive track record of investment management across both public and private markets within APAC. BiomeBank’s Series A funding round anticipated to close in early 2022. Formal Therapeutic Goods Association (“TGA”) approval of…

0 Comments

BiomeBank Submits for Market Authorisation of World First Microbial Therapy

ADELAIDE, South Australia--(BUSINESS WIRE) The company behind Australia’s first facility for the manufacturing of microbial therapies has set its sights on global impact, applying to the Therapeutic Goods Administration, Australia’s regulatory authority, for approval of their world-first biologic drug product. “In addition to our existing syringe-based therapy, we are also developing capsule based-products that will…

0 Comments

Faecal transplants to help treat symptoms of Parkinson’s

Media Release Revolutionary faecal transplants are the latest new treatment option being trialled in people living with Parkinson’s to help manage their debilitating symptoms by replenishing their healthy gut bacteria. The trial is the result of an exciting collaboration between leading Australian biotechnology company BiomeBank, the Departments of Neurology, Nuclear Medicine and Gastroenterology within the Royal…

0 Comments